Despite the fact that IDO2 action in adenocarcinomas and in adenocarcinoma patterns may differ from that of IDO1 (6, 11, 14, 17–19, 24–26), we could speculate about the existence of other immunosuppressive mechanisms induced by IDO2 in this NSCLC subgroup. Here, IDO2 is linked to non-small cell lung carcinoma.